$CLSD
Clearside Biomedical, Inc.

2017 Q1 Form 10-Q Financial Statement

#000156459017010255 Filed on May 10, 2017

View on sec.gov

Income Statement

Concept 2017 Q1 2016 Q1
Revenue $5.000K $505.0K
YoY Change -99.01%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.670M $1.270M
YoY Change 110.24% 1.6%
% of Gross Profit
Research & Development $7.590M $4.589M
YoY Change 65.4% 82.83%
% of Gross Profit
Depreciation & Amortization $30.00K $17.00K
YoY Change 76.47% -15.0%
% of Gross Profit
Operating Expenses $10.26M $5.862M
YoY Change 75.04% 56.03%
Operating Profit -$10.26M -$5.357M
YoY Change 91.45%
Interest Expense -$90.00K
YoY Change
% of Operating Profit
Other Income/Expense, Net -$117.0K -$92.00K
YoY Change 27.17%
Pretax Income -$10.37M -$5.450M
YoY Change 90.28% 44.95%
Income Tax
% Of Pretax Income
Net Earnings -$10.37M -$5.449M
YoY Change 90.37% 45.04%
Net Earnings / Revenue -207460.0% -1079.01%
Basic Earnings Per Share
Diluted Earnings Per Share -$410.7K -$278.2K
COMMON SHARES
Basic Shares Outstanding 25.29M
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q1 2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $77.50M $15.90M
YoY Change 387.42%
Cash & Equivalents $22.99M $15.89M
Short-Term Investments $54.50M
Other Short-Term Assets $3.000M $100.0K
YoY Change 2900.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $80.50M $16.00M
YoY Change 403.13%
LONG-TERM ASSETS
Property, Plant & Equipment $1.000M $100.0K
YoY Change 900.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $500.0K $800.0K
YoY Change -37.5%
Total Long-Term Assets $1.500M $900.0K
YoY Change 66.67%
TOTAL ASSETS
Total Short-Term Assets $80.50M $16.00M
Total Long-Term Assets $1.500M $900.0K
Total Assets $82.00M $16.90M
YoY Change 385.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.700M $2.500M
YoY Change 88.0%
Accrued Expenses $1.500M $2.500M
YoY Change -40.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $800.0K $2.300M
YoY Change -65.22%
Total Short-Term Liabilities $7.200M $7.300M
YoY Change -1.37%
LONG-TERM LIABILITIES
Long-Term Debt $6.900M $3.700M
YoY Change 86.49%
Other Long-Term Liabilities $700.0K $400.0K
YoY Change 75.0%
Total Long-Term Liabilities $7.600M $4.100M
YoY Change 85.37%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.200M $7.300M
Total Long-Term Liabilities $7.600M $4.100M
Total Liabilities $14.80M $11.40M
YoY Change 29.82%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $67.20M $5.500M
YoY Change
Total Liabilities & Shareholders Equity $82.00M $16.90M
YoY Change 385.21%

Cashflow Statement

Concept 2017 Q1 2016 Q1
OPERATING ACTIVITIES
Net Income -$10.37M -$5.449M
YoY Change 90.37% 45.04%
Depreciation, Depletion And Amortization $30.00K $17.00K
YoY Change 76.47% -15.0%
Cash From Operating Activities -$10.98M -$4.400M
YoY Change 149.55% 17.33%
INVESTING ACTIVITIES
Capital Expenditures $309.0K $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$5.680M $0.00
YoY Change
Cash From Investing Activities -$5.990M $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.130M 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -10.98M -4.400M
Cash From Investing Activities -5.990M 0.000
Cash From Financing Activities 5.130M 0.000
Net Change In Cash -11.84M -4.400M
YoY Change 168.98% 17.33%
FREE CASH FLOW
Cash From Operating Activities -$10.98M -$4.400M
Capital Expenditures $309.0K $0.00
Free Cash Flow -$11.29M -$4.400M
YoY Change 156.57% 17.33%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q1 us-gaap Licenses Revenue
LicensesRevenue
505000
CY2016Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2000
CY2016Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-505000
CY2016Q1 clsd Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
3000
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-4396000
CY2017Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
309000
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-5990000
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1273000
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4589000
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
5862000
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5357000
CY2016Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-92000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-5449000
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.05
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2660370
CY2017Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-8000
CY2017Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10381000
CY2016Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5449000
CY2017Q1 us-gaap Depreciation
Depreciation
30000
CY2016Q1 us-gaap Depreciation
Depreciation
17000
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
752000
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
260000
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-10978000
CY2017Q1 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
12656000
CY2017Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
52000
CY2016Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
38000
CY2017Q1 us-gaap Deferred Finance Costs Own Share Lending Arrangement Issuance Costs Amortization Expense1
DeferredFinanceCostsOwnShareLendingArrangementIssuanceCostsAmortizationExpense1
53000
CY2016Q1 us-gaap Deferred Finance Costs Own Share Lending Arrangement Issuance Costs Amortization Expense1
DeferredFinanceCostsOwnShareLendingArrangementIssuanceCostsAmortizationExpense1
21000
CY2017Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-18000
CY2017Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
6975000
CY2017Q1 us-gaap Licenses Revenue
LicensesRevenue
5000
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7590000
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2671000
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
10261000
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-10256000
CY2017Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-117000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-10373000
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.41
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
25250333
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2305000
CY2016Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-119000
CY2017Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
62000
CY2016Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
6000
CY2017Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
872000
CY2016Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1114000
CY2017Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-5000
CY2017Q1 clsd Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
10000
CY2017Q1 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
860000
CY2017Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
2770000
CY2017Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
39000
CY2016Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
20000
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
5133000
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-11835000
CY2017Q1 clsd Proceeds From Issuance Follow On Public Offering
ProceedsFromIssuanceFollowOnPublicOffering
5057000
CY2017Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
76000
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-4396000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20283000
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15887000
CY2017Q1 clsd Noncash Tenant Improvements Paid By Landlord
NoncashTenantImprovementsPaidByLandlord
637000
CY2017Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
117000
CY2016Q1 clsd Deferred Initial Public Offering Costs In Accounts Payable And Accrued Expenses
DeferredInitialPublicOfferingCostsInAccountsPayableAndAccruedExpenses
384000
CY2016Q1 clsd Accretion Of Redeemable Convertible Preferred Stock To Redemption Value
AccretionOfRedeemableConvertiblePreferredStockToRedemptionValue
72000
CY2017Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of income and expenses during the reporting periods. Significant items subject to such estimates and assumptions include the accounting for useful lives to calculate depreciation and amortization, clinical trial estimates and related accrued liabilities, share-based compensation expense and income tax valuation allowance. Actual results could differ from these estimates.</p></div>
CY2017Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk Arising From Cash Deposits in Excess of Insured Limits</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The Company maintains its cash in bank deposits that at times may exceed federally insured limits. The Company has not experienced any loss in such accounts. The Company believes it is not exposed to any significant risks with respect to its cash balances.</p></div>
CY2017Q1 clsd Long Term Debt Maturities Repayments Of Principal Interest And Final Payment In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInterestAndFinalPaymentInYearTwo
3676000
CY2017Q1 clsd Long Term Debt Maturities Repayments Of Principal Interest And Final Payment In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInterestAndFinalPaymentInYearThree
3434000
CY2017Q1 clsd Long Term Debt Maturities Repayments Of Principal Interest And Final Payment In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInterestAndFinalPaymentInYearFour
2145000
CY2017Q1 clsd Long Term Debt Maturities Repayments Of Principal Interest And Final Payment
LongTermDebtMaturitiesRepaymentsOfPrincipalInterestAndFinalPayment
9713000
CY2017Q1 clsd Non Cancelable Operating Leases Expiration Month And Year
NonCancelableOperatingLeasesExpirationMonthAndYear
2017-03
CY2017Q1 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
105000
CY2016Q1 us-gaap Interest Expense Borrowings
InterestExpenseBorrowings
45500
CY2017Q1 clsd Accretion Of Final Payment Of Amount Borrowed
AccretionOfFinalPaymentOfAmountBorrowed
52000
CY2016Q1 clsd Accretion Of Final Payment Of Amount Borrowed
AccretionOfFinalPaymentOfAmountBorrowed
38000
CY2017Q1 clsd Accretion Of Deferred Closing Costs
AccretionOfDeferredClosingCosts
53000
CY2016Q1 clsd Accretion Of Deferred Closing Costs
AccretionOfDeferredClosingCosts
21000
CY2017Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
3200000
CY2017Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
3200000
CY2017Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
1600000
CY2017Q1 us-gaap Long Term Debt
LongTermDebt
8000000
CY2017Q1 clsd Long Term Debt Maturities Repayments Of Interest And Final Payment Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfInterestAndFinalPaymentRemainderOfFiscalYear
458000
CY2017Q1 clsd Long Term Debt Maturities Repayments Of Interest And Final Payment In Year Two
LongTermDebtMaturitiesRepaymentsOfInterestAndFinalPaymentInYearTwo
476000
CY2017Q1 clsd Long Term Debt Maturities Repayments Of Interest And Final Payment In Year Three
LongTermDebtMaturitiesRepaymentsOfInterestAndFinalPaymentInYearThree
234000
CY2017Q1 clsd Long Term Debt Maturities Repayments Of Interest And Final Payment In Year Four
LongTermDebtMaturitiesRepaymentsOfInterestAndFinalPaymentInYearFour
545000
CY2017Q1 clsd Long Term Debt Maturities Repayments Of Interest And Final Payment
LongTermDebtMaturitiesRepaymentsOfInterestAndFinalPayment
1713000
CY2017Q1 clsd Long Term Debt Maturities Repayments Of Principal Interest And Final Payment Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalInterestAndFinalPaymentRemainderOfFiscalYear
458000
CY2017Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2011-05-26
CY2017Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
77500000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
66800000
CY2017Q1 clsd Short Term Investments Maturity Period Range Start
ShortTermInvestmentsMaturityPeriodRangeStart
P90D
CY2017Q1 clsd Short Term Investments Maturity Period Range End
ShortTermInvestmentsMaturityPeriodRangeEnd
P365D
CY2017Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1105000
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
262000
CY2017Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
95000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
168000
CY2017Q1 clsd Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
646000
CY2016Q4 clsd Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
1153000
CY2017Q1 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
244000
CY2016Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
870000
CY2017Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
143000
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
410000
CY2017Q1 us-gaap Accrued Vacation Current
AccruedVacationCurrent
137000
CY2016Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
72000
CY2017Q1 us-gaap Interest Payable Current
InterestPayableCurrent
54000
CY2016Q4 us-gaap Interest Payable Current
InterestPayableCurrent
52000
CY2017Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
317000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
234000
CY2017Q1 us-gaap Interest Expense Borrowings
InterestExpenseBorrowings
156000
CY2017Q1 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
431000
CY2017Q1 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
444000
CY2017Q1 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
458000
CY2017Q1 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
472000
CY2017Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
54483000
CY2017Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
21000
CY2017Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
77811000
CY2016Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
83991000
CY2017Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2208888
CY2016Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10901393

Files In Submission

Name View Source Status
0001564590-17-010255-index-headers.html Edgar Link pending
0001564590-17-010255-index.html Edgar Link pending
0001564590-17-010255.txt Edgar Link pending
0001564590-17-010255-xbrl.zip Edgar Link pending
clsd-10q_20170331.htm Edgar Link pending
clsd-20170331.xml Edgar Link completed
clsd-20170331.xsd Edgar Link pending
clsd-20170331_cal.xml Edgar Link unprocessable
clsd-20170331_def.xml Edgar Link unprocessable
clsd-20170331_lab.xml Edgar Link unprocessable
clsd-20170331_pre.xml Edgar Link unprocessable
clsd-ex311_6.htm Edgar Link pending
clsd-ex312_8.htm Edgar Link pending
clsd-ex321_7.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending